#ESMO26 | POP-DURVA
In stage I TNBC, the clinical and immunological effects of a single dose of durvalumab without chemo were evaluated (n=71).
- pCR: 1.7%
- Objective response: 11.6%
- Tumor shrinkage: 41.3%
- Conversion to an inflamed phenotype: 33% of initially immune-negative tumors.
A single dose of immunotherapy induced substantial immune activation, but pathological response was very limited.
The main value of this study lies in identifying potential biomarkers of immunotherapy sensitivity rather than demonstrating the efficacy of a chemo-free approach.
However, results after only 15 days of treatment cannot establish the efficacy of longer-term monotherapy.
432 views · 4 likes · 4 reposts · 0 replies
Durvalumab plus definitive chemoradiotherapy versus definitive chemoradiotherapy in patients with locally advanced esophagus carcinoma: ARION PRODIGE 67 randomized phase 2 trial
https://esmocongress.esmo.orgDurvalumab (D) in Combination With BCG Induction and Maintenance (I+M) for BCG-Naïve, High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): Early Recurrence and Cystectomy-Free Survival in Patients (pts) With Papillary Only Tumours From POT
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgShort-term preoperative durvalumab for stage I TNBC: First results from the phase II UNLOCK 14 - POP-DURVA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDurvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.orgSource: Yakup Ergün · x.com